

Dean Sherzai, MD, PhD, MPH, MAS, Roman Moness, Sophia Sherzai, and Ayesha Sherzai, MD

A Systematic Review of Omega-3 Fatty Acid Consumption and Cognitive Outcomes in Neurodevelopment

Abstract: Introduction: This systematic review addresses the effects of n-3 long-chain polyunsaturated fatty acids consumption on human neurodevelopment. It evaluates articles published between 2000 and 2022 investigating the cognitive outcomes during the period of neurodevelopment: from fetal development to adolescence. For the purpose of this review the terms LC PUFA and omega-3 fatty acid will be used interchangeably. Method: Data were sourced from several major databases including PubMed (MEDLINE), Web of Science, and ProQuest Central. Randomized controlled trials (RCTs), nonrandomized controlled trials, prospective or retrospective cohort studies, and observational studies investigating the effects of omega-3 fatty acid consumption from dietary supplements, multiple-nutrient supplement, or food questionnaire on neurodevelopment were considered. Study population was separated in three developmental phases: (1) inutero, (2) lactation/infancy, and (3) childhood/adolescence. Each article

was evaluated for several key factors such as study type, type/dosage of PUFAs, number of subjects, length of intervention, participant age range, population characteristics, outcome measure (both primary/cognitive and secondary/other), results, conclusion, and confounding variables/limitations. Results: A total of 88 articles were included in the

supplement might have a short-term positive impact on neurodevelopment in all three phases. Supplementation is recommended throughout life, rather than only during the earliest developmental stage.

Keywords: omega-3s; LC PUFAs; cognition; neurodevelopment

Although LC PUFAs supplied during infancy and in-utero seldom have shown significant cognitive effects, it appears that they do not persist at long-term follow-up assessments.

review, 69 RCTs and 19 longitudinal or observational studies. The results indicate equivocal effect of intervention, with some short-term benefits observed in the areas of visual attention, working memory, executive function, and communication. Omega-3

Introduction

As the most lipid-dense organ of the body, after adipose tissue, the brain requires fatty acids for purposes of fluidity, function, and structure.¹ Importantly, neither omega-3 $(n-3)$ nor omega-6 $(n-6)$ long-chain

DOI: [10.1177/15598276221116052](https://doi.org/10.1177/15598276221116052). Dept of Neurology, Brain Health and Alzheimer's Prevention Program, Loma Linda University, Loma Linda, CA, USA (AS, DS); Oak Ridge High School, El Dorado Hills, CA, USA (RM); California State University, Los Angeles, CA, USA (SS). Address correspondence to: Ayesha Sherzai, Dept of Neurology, Brain Health and Alzheimer's Prevention Program, Loma Linda University, 11370 Anderson St, Suite B-100, Loma Linda, CA 92354, USA; e-mail: [azsherzai@gmail.com;](mailto:azsherzai@gmail.com) asherzai@llu.edu.

For reprints and permissions queries, please visit SAGE's Web site at [http://www.sagepub.com/journalsPermissions.nav.](http://www.sagepub.com/journalsPermissions.nav) Copyright © 2022 The Author(s).

polyunsaturated fatty acids (LC PUFAs) can be synthesized *de novo* in human cells, meaning that dietary sources are important throughout life, particularly during several key, sensitive periods. Fatty acids affect white matter tracts in terms of myelination and fiber integrity, thereby influencing neural signaling.^{[2](#page-33-1)} Among LC PUFAs, docosahexaenoic acid, (DHA; $22:6$, $n-3$) has received the most extensive attention throughout extant research, since it has the highest concentration in the brain; however, studies have also addressed eicosapentaenoic acid (EPA), alpha-linolenic acid (ALA), arachidonic acid (AA/ARA), and the importance of LC PUFA ratios. The frontal lobe, where complex cognitive processes occur, has a high concentration of DHA, which has a significant role in membrane fluidity and signal transmission.^{3[-5](#page-33-3)}

Westernization and the move toward diets with higher percentages of processed foods and lower consumption levels of dietary $n-3$ sources have led to concerns about population LC PUFA levels. Indeed, estimates of this shift suggest that traditional diets with 1:1 ratios of $n-6$ to $n-3$ PUFAs have been replaced by ratios closer to 20:1.^{[6](#page-33-4)}

Omega-3 Fatty Acid and In-Utero Cognitive Development

The prenatal period is the most frequently cited sensitive period during which $n-3$ LC-PUFAs are important to cognitive development. Based on epidemiological studies conducted in regions with high levels of fish intake, researchers identified a potential correlation between the maternal consumption of EPA and DHA and factors including gestational length and birth weight.^{[1](#page-33-0)}

During the third trimester an upsurge of PUFA accretion, primary DHA, in fetal brain matter occurs at a rate of 70 mg per day due to an increased cellular synthesis.^{[1,](#page-33-0)[7](#page-33-5)} The accumulation of LC PUFAs is particularly important in the frontal

lobe and hippocampus, areas associated with higher-order cognitive functioning.^{[8](#page-33-6)}

DHA supplementation has been previously related to extended gestational length, increased birth weight, and neurodevelopment.⁹ Given that the third trimester is a significant period during which PUFAs are deposited in the fetal brain, many studies have attempted to identify deficiencies in or the effects of supplementation on preterm infants. Recently, the attention on the role of DHA in fetal development has been increased, and, in connection with concerns about consuming mercurycontaining fish during pregnancy, the consumption of prenatal fish-oil and other $n-3$ supplements have increased.

Omega-3 Fatty Acid and Cognitive Development During Infancy. Supplementation with $n-3$ LC PUFAs during the infancy phase of development has its foundation in the longstanding research on the advantages of breastfeeding for cognitive development, and questions regarding whether this is due to the composition of human milk (including DHA), or other demographic factors associated with the decision to breastfeed.^{[10,](#page-33-8)[11](#page-33-9)} Studies conducted during infancy have highlighted a positive correlation between PUFA supplementation and both cognitive and visual functions due to the PUFA accretion in fetal brain and retinal tissue, Supplementation studies during infancy have largely been focused on DHA, often in combination with EPA and AA, given their role in various neural processes including synapse maturation, processing speed, and the structure of the neuronal membrane.[3,](#page-33-2)[11](#page-33-9)

Omega-3 Fatty Acid and Cognitive Development During Childhood and Adolescence. While the third trimester of pregnancy and first 18 months of life are particularly

significant phases of $n-3$ accretion in brain and retinal tissue, it is important to consider the continued process of cognitive development in early childhood and adolescence, and clarify the neurodevelopmental effects of LC PUFAs in this later phase. Researchers focusing on this age group are particularly driving attention to pathologies that affect cognitive development, including attention-deficit/hyperactivity disorder (ADHD), phenylketonuria, and autism spectrum disorder (ASD).

Review Objective. Omega-3 LC-PUFAs function as cell membrane components, tissue formation and neuroprotection has been largely proved.^{[12](#page-33-10)} However, omega-3 supplement effect on neurodevelopment addressed in a large number of studies and reviews have reported controversial conclusions. Therefore, the need of a comprehensive review to extrapolate and evaluate data from studies published in the last 2 decade. In this review we summaries the finding on the effect of omega-3

supplementation on cognitive development across three neurodevelopmental periods: (1) inutero, (2) lactation/infancy, and (3) childhood and adolescence. The objective is to evaluate the efficacy of omega-3 supplementation on neurodevelopment in different brain developmental phases from in-utero to adolescence.

Methodology

For the purposes of this comprehensive review, we searched PubMed (MEDLINE), Web of Science, and ProQuest Central, using filters for peer-reviewed articles published between 2000 and 2022. Search terms included: omega-3s; docosahexaenoic acid (DHA); cognitive function; macronutrients; healthy fats; polyunsaturated fatty acids; brain health; developmental outcomes; $n-3$ polyunsaturated fats;

LC PUFAs; dietary fats; and brain function.

Study Selection

Both the authors (DS and AS) were involved in the literature search, screening for eligible studies, and review. After articles were identified, the authors thoroughly reviewed titles, abstracts, and full texts, and selected the included ones according to the inclusion/exclusion criteria. Duplicate were eliminated. To confirm the comprehensiveness of the literature included, the Authors also consulted the reference lists of all articles published in the last 5 years, as well as previous literature review and meta-analysis articles, and used the "cited by" function in a university library database-wide search; additional abstracts were reviewed, and appropriated articles were included.

Inclusion and Exclusion Criteria

The authors defined inclusion and exclusion criteria a priori and included the following study designs: randomized controlled trials (RCTs), nonrandomized controlled trials, prospective or retrospective cohort studies, case-control studies, and observational studies. Only articles written in English published between 2000 and 2022 were included. Studies investigating the effects of omega-3 fatty acid intake from dietary supplements or multiple-nutrient supplement on cognition, or studies analyzing dietary omega-3 intake through a food questionnaire were considered. The populations included were: (i) in-utero, (ii) lactation/infancy, and (iii) childhood and adolescence. Case studies and studies in which PUFAs supplementation was not a primary (or differentiable) independent variable were not considered in this review.

Data Extraction

Included articles were analyzed and data were extracted using

a custom data extraction form developed by DS and AS. The outcome of interests for the in-utero population were: communication and language, attention tasks, and visual development. For the lactation/infancy were: communication, intelligence, working memory, attention, and problem solving. For the childhood and adolescence population were: attention and executive functioning, information processing, speeds and impulsivity, memory, and cognitive pathologies.

After publication analysis, we extracted the following categories: study type, LC PUFA dosage and composition, sample number, length of intervention, subjects age, and population characteristics. Study characteristics and outcomes were also extrapolated. We reported: primary and secondary outcome (eg cognitive tests result, memory function, learning test), summary of result and conclusion, study limitation and funding sources.

Results

The literature search resulted in a total of 501 articles. Articles initially excluded were duplicates $(n = 120)$, animal studies ($n = 68$), studies not focusing on omega-3 (88), studies with non-cognitive outcomes measure $(n = 33)$. We reviewed the abstract of the remaining 181 articles and selected 81 pertaining to neurodevelopment to read in full. We narrowed these to a final set of 71 articles that met the inclusion criteria. To have a more comprehensive review, we expanded the search to the reference list of the included articles and reviewed an additional 34 abstracts of which 17 were included.

Of the 82 included articles, 26 investigated omega-3 prenatal supplementation (8 RCTs, 12 revision of RCTs, and 6 observational studies), 26 investigated omega-3 supplementation during infancy (19 RCT, 4 previous RCTs, and 3 observational studies), and 36 articles investigated omega-3 supplementation during childhood and adolescence (25 RCTs, 7 observational studies, and 4 secondary analyses of previous RCTs).

In-Utero Supplementation

To our knowledge, only two large scale $(N > 500)$ studies have been conducted on humans to assess the cognitive outcomes of $n-3$ LC PUFA supplementation *in-utero*: the DOMInO trial, 13 13 13 and the POSTGRAD cohort study.^{[14](#page-33-12)} Study sample sizes for the remaining included publications ranged from 76 to 350.

The studies included in this review primarily assessed the effect of omega-3 DHA supplementation ($n =$ 9). In the included studies DHA dosage levels ranged from 220 mg to 800 mg per day. Rees et al. also assessed for DHA levels, but via a food frequency questionnaire rather than a supplementation intervention. 15 15 15 In the remaining studies DHA was combined with EPA , $^{16-19}$ $^{16-19}$ $^{16-19}$ $^{16-19}$ and AA.^{[20](#page-33-16)} In terms of intervention lengths, the studies reviewed here featured gestational supplementation ranging from week 12 to week 22 of gestation. The studies used a broad range of cognitive outcome measures, with the Kaufman Assessment Battery for Children (K-ABC) appearing most frequently.

Importantly, while most studies cited academic and/or governmental funding sources, industry interests also appeared as financial contributors to several of the studies: a company that produces omega-3 supplements^{[18,](#page-33-17)[19](#page-33-15),[21](#page-33-18)}; a dairy industry stakeholder 20 20 20 ; and a nutrition company.[15](#page-33-13) [Table 1](#page-3-0) presents the study and population characteristics of the 26 studies included in this analysis of in-utero supplementation studies.[22-](#page-33-19)[32](#page-34-0) [Table 2](#page-5-0) provides the instrumentation, results, and

Table 1.

In-Utero Supplementation Studies: Study Types and Participant Characteristics.

Table 1. (continued)

limitations information for the included studies.

Overall, the extant RCTs and RCT follow-up studies that feature inutero n-3 LC PUFA supplementation have yielded mixed results. The largest study to date, the DOMInO

trial ($N = 2399$; follow-up with 726 children), found that DHA supplementation during pregnancy had no significant effect on either maternal depression levels 6 months postpartum or the children's mean cognitive composite or mean

language composite scores on the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III). Importantly, these null results are at odds with those of previous epidemiological studies, which the authors noted may have

Table 2.

In-Utero Supplementation Studies: Instrumentation, Results, and Limitations.

Table 2. (continued)

Table 2. (continued)

Table 2. (continued)

overestimated effect sizes, and those of some smaller studies that have reported positive outcomes.

The studies included in this review that did yield positive

outcomes of supplementation focused on communication and language, attentional tasks, and visual development. However, results in those areas are also

mixed. Further, most studies that included a long-term follow-up largely reported that, even when positive outcomes were identified at a short-term follow-up, these

outcomes often failed to persist at longer-term assessments.

Communication and Language. Several studies that assessed cognitive measures identified positive outcomes of $n-3$ LC PUFA supplementation and communication and language. The results of an RCT conducted in Iran found prenatal fish oil supplementation to be beneficial for neurodevelopment, but only in the communication domain, among infants at 4 months. 33 Similarly, although Mulder et al. did not report childhood neurodevelopment benefits of supplementation *in-utero*, the Authors did find higher maternal DHA level to be correlated to higher language scores on the K-ABC at 5-6 years of age.^{[34](#page-34-2)} While Colombo et al. found maternal blood DHA to correlate with higher verbal IQ at 5-6 years, this was not the case after controlling for the socioeconomic status.^{[35](#page-34-3)}

Attentional Tasks. One of the key findings for this cognitive developmental phase is the indication that prenatal supplementation with $n-3$ LC PUFAs has positive effects on infantile attention. Notably, the results of a large RCT (the Kansas University DHA Outcomes Study [KUDOS]) that assessed visual habituation among 4-, 6-, and 9-month-old infants whose mothers had been prenatally supplemented with DHA, indicate that maternal DHA supplementation correlated with improved performance on sustained attention and behavioral state tests during the first year of life.^{[36](#page-34-4)} In a secondary analysis of the DOMINO trial assessing the prenatal effects of DHA on working memory and inhibitory control (WMIC), no difference between the control and the treatment group were observed.^{[9](#page-33-7)}

While the results of the study by Ramakrishnan et al. did not indicate an effect of supplementation on general cognitive scores or MSCA subscales, children in the intervention group did make fewer omissions on the Conners' Kiddie Continuous Performance Test (K-CPT), which is used to measure attention. 14 14 14 The results of that study also indicate that $n-3$ LC PUFA supplementation attenuated the effect of home environment on cognition, suggesting the importance of DHA supplementation for children with less stimulating home environments.

Visual Development. In addition to its role in fetal brain tissue development, $n-3$ LC PUFAs play a significant role in retinal development; therefore, several studies have addressed prenatal $n-3$ supplementation in relation to visual acuity and cognitive-associated visual and attention tasks. Dunstan et al. found hand-eye coordination scores on the Griffiths Mental Development Scales (GMDS) to be correlated with cord blood $n-3$ LC PUFA levels.^{[17](#page-33-20)} In Hurtado et al. study there was not a correlation between supplementation with $n-3$ LC PUFAs during pregnancy or during lactation on neurodevelopment outcomes, or on visual acuity for the sample as a whole.^{[37](#page-34-5)} However, when stratification was done by gender, supplementation did cause visual acuity to improve for boys, but not for girls. Rees et al¹⁵ conducted a visual acuity test and found that children whose mothers were in the moderate DHA intake group performed the best on this measure at 9 months, and that this finding was only significant in relation to third-trimester DHA levels.^{[15](#page-33-13)} However, the results did not indicate any significant difference in habituation and visual attention levels in relation to DHA levels.

Long-Term Effects. Although several studies found $n-3$ LC PUFA supplementation having beneficial

effects during follow-up assessment conducted on younger children, reported controversial outcome with more negligible results. A follow-up to the Nutraceuticals for a Healthier Life (NUHEAL) cohort found that, at 6.5 years of age, prenatal DHA supplementation (500 mg DHA daily) did not correlate with K-ABC scores.^{[16](#page-33-14)} Similarly, a long-term follow-up to the KUDOS study revealed that, while prenatal DHA supplementation produced positive attention development outcomes during the first year of life, positive effects tended to dissipate at older ages.^{[35](#page-34-3)} For example, a significant correlation between supplementation and rule learning and flexibility was seen at 36 months, but not at older ages. Correlations between supplementation and attention and spatial memory that were observed at 24 and 36 months did not persist at older ages, and the significance of these findings decreased when the researchers controlled for sex and task variables. Also, while maternal blood DHA level during pregnancy correlated with higher IQ at 5-6 years of age, this finding disappeared entirely when the researchers controlled for SES.^{[35](#page-34-3)} The lack of long-term effects may have been due to the fact that both placebo and intervention groups obtained sufficient levels of LC PUFAs for cognitive development postnatally.

Similarly, although Mulder et al. found DHA insufficiency during gestation to be associated with risk of failing to achieve high neurodevelopmental test scores at 18 months of age, by 5.75 years of age, these results had dissipated.^{[34](#page-34-2)} However, maternal DHA status was related to child scores on some language and short-term memory scales of the K-ABC.

Helland at al. found that, while higher umbilical plasma DHA level did correlate with longer length of gestation, the groups did not show any cognitive differences at 6- or 9month follow-ups.^{[18](#page-33-17)} While the original study by Helland et al. did not report a correlation between cod liver oil supplementation during pregnancy and lactation and scores on the Fagan test for novelty preference at 6 or 9 months of age, a follow-up study on the original cohort reveled that, at 4 years of age, the children in the cod liver oil group scored an average of 4.1 points higher on the mental processing composite of the K-ABC.^{[21](#page-33-18)} While this result suggests that $n-3$ LC PUFA supplementation improves the intelligence of children at the age of 4, the researchers were unable to discern whether this result should be attributed to supplementation during pregnancy, lactation, or both. In a second follow-up study, however, Helland et al. did not find a difference in intelligence scores for children at 7 years of age, excepting insignificantly higher sequential processing scores among members of the intervention group. 19 However, by this time, the effects of supplementation may have been diluted by other diet and lifestyle factors; parental education level was also identified as a significant confounding variable.

Confounding Variables. In some cases, demographic variables were found to potentially skewing study results. For example, a secondary analysis of the DOMInO trial was conducted to assess whether maternal smoking status, maternal education, and socioeconomic status mediated the results. The adverse effects of smoking tended to negate the positive effects of DHA supplementation during pregnancy, and 18-month Bayley-III cognitive composite scores were higher for children in the DHA supplementation group, but only when their mothers had not completed further education.^{[9](#page-33-7)}

Supplementation During Infancy

In the 26 included studies assessing the effects of $n-3$ LC PUFA supplementation during infancy, the non-intervention studies featured analysis of FA levels in maternal human milk, cord levels, and supplementation via formula; supplementation studies featured maternal $n-3$ supplementation; supplemented human milk; supplemented formula; or direct supplementation to the infant independent of feeding. FA supplementation sources included fish oil, borage oil, and egg yolk, and various ratios of DHA, EPA, and AA (see [Table 3](#page-12-0) for more detail). $38-50$ $38-50$ Sample sizes ranged from 52 to 604, and intervention lengths ranged from 9 weeks to 1 year. Ten of these studies were wholly or partially funded by organizations with interests in infant formula manufacturing or nutritional supplements.

The majority of studies were conducted in high-income countries where LC PUFA levels are often already sufficient, and numerous authors mentioned the possibility of a threshold/lack of deficiency as a potential explanation for their null results. The study by van der Merwe et al. is unique in having been conducted in a low-income country where infants were presumably more likely to suffer from adverse effects from $n-3$ LC PUFA deficiencies. 51 While no cognitive effects were reported, and maternal human milk FA levels were higher than anticipated, that study does highlight the issues with conducting research among affluent populations and in countries with high fish intake levels, as cognitive differences may be more detectable when deficiencies are present [Table 4](#page-16-0).

In general, LC PUFA supplementation during the early neonatal phase is done by supplementing lactating mothers or providing infant supplementation through DHA-containing formula or supplemented human milk. Effects of direct LC PUFA supplementation has been tested by Meldrum et al. which supplemented infants between birth and 6 months with a high-dose DHA-enriched ethyl ester Fatty Oil (FO).^{[52](#page-35-1)} Van der Merwe et al. also administered FO to the infant before breastfeeding. 51 Both studies failed to show any difference between treated group and control, however Meldrum et al. reported some benefits to early communicative development [Table 5.](#page-20-0)

Dalmeijer et al. assessed the potential role of PUFAs benefits during breastfeeding, comparing with a control non-breastfed cohort (at the time of the study, formulas did not include PUFAs in the Netherlands). In 3 months old infants the results indicated some correlation between DHA level in human milk and higher scores on the Cito school standardized test; however, this was only true of girls, which indicates that sex-specific differences in ability to metabolize n-3 LC PUFAs require further investigation.^{[53](#page-35-2)}

Supplements in Very Low Birth Weight Infants. FA insufficiency during the third-trimester has been correlated to fetal brain development, premature birth, and very low birth weight (VLBW). Considering that VLBW children have increased risk of behavioral problems, Almaas et al. suggested that DHA supplement to VLBW infants would influence cerebral white matter and improve behavioral outcome. Results did not indicate significant differences between control and intervention groups for both the outcomes.^{[2](#page-33-1)}

Henriksen et al. tested the effect of DHA and AA supplementation in 129 VLBW infants fed human milk. The follow-up lasted 8 years, and whereas no differences in growth or

Table 3.

Supplementation during Infancy: Study Type and Participant Characteristics.

Table 3. (continued)

intelligence quotient (IQ) were found, blood DHA at 8 years was positively associated with IQ[.54](#page-35-3)

Specific Outcomes of Interest. A limitation of previous research on LC PUFA supplementation during infancy is the lack in assessing specific cognitive domains. More recent studies conducted over the past 2 decades have endeavored the

use of subscales and specific measures to access the cognitive function effects of FA supplementation during infancy. As such, the results of this review are organized according to the following cognitive domains: Communication, Intelligence, Working Memory, Programming During Brain Development, Attention, Problem Solving [Table 6.](#page-25-0)

Communication. As addressed in the in-utero supplementation section, Ostadrahimi et al. conducted a study with a supplementation range including both in-utero and lactation periods, and found that—of five neurodevelopment domains assessed at each age—only the communication domain had a positive correlation with fish oil supplementation, and only at

 4 months of age.^{[33](#page-34-1)} However, negative language results have also been reported. Cheatham et al. found language and prosocial scores to be lower, only among boys, in the fish oil supplementation group than in the control group.³

While they did not find a significant effect of DHA supplementation during the first 9 months of life on

overall cognitive function at 10 years of age, Isaacs et al. did find that girls in the supplemented group performed better on the reading and spelling measures of the Weschler Individual Achievement test.^{[55](#page-35-4)} However, both groups that received human milk scored higher on the Weschler subscales, again prompting the question of whether

DHA or another factor associated with breastfeeding accounted for this correlation. While Meldrum et al. found that infants supplemented with FO exhibited higher gestural scores—important in relation to gesture as a precursor to language the overall results of the study were inconclusive due to methodological issues including discrepant sample sizes across outcome measures and a high rate of correctly guessed group allocation, which may have introduced bias.[54](#page-35-3)

Intelligence. In an early study on DHA supplementation during infancy, Birch et al. found that supplementation with DHA and AA during infancy correlated with an increase of 7 points on the BSID-II mental development index (MDI).⁷ The cognitive and motor subscales of the MDI were significantly higher among both the DHA and DHA + AA groups, and the language scores were higher, but not significantly so. Isaacs et al. found that, while there were no overall differences in cognitive outcomes between the groups, 10 year-old girls in the supplemented group demonstrated improved performance in reading and spelling measures of the Weschler Individual Achievement test.^{[55](#page-35-4)}

While an 8-year follow-up study did not indicate any effect of supplementation during infancy on IQ, Henriksen et al. did find DHA level assessed at the time of the follow-up to correlate with higher IQ scores after correcting for maternal education and birth weight.⁵⁶ Willatts et al. did not find any difference in IQ scores among control or intervention (formula supplemented with egg yolk) group children at 6 years of age, but noted that the global testing measure may not be sufficiently sensitive to detect group differences.¹¹

Working Memory. Henriksen et al. reported a significant benefit of DHA and AA supplementation

Table 4.

Supplementation during Infancy: Instrumentation and Results.

Table 4. (continued)

Table 4. (continued)

668

during infancy on working memory, tested using event related potentials.[56](#page-35-5) They also reported that the test required infants to be relatively calm, and that agitated infants were excluded from the analyzed sample.Programming During Brain Development

Liao et al. found that participants in the intervention groups exhibited activation of a larger, synchronized neuronal network than the control group, suggesting that early LC PUFA supplementation can have an important programming effect on the brain during development.^{[57](#page-35-6)}

Attention. Westerberg et al. found that intervention group infants demonstrated more time sequences with a high level of attention during free play sessions than the control group, as well as higher levels of sustained attention among members of the intervention group.^{[58](#page-35-7)} Higher DHA levels at hospital discharge did correlate with better sustained attention levels and MDI scores, but due to loss to follow-up, the study's ability to detect small betweengroup differences was limited, and the results may be attributable to

chance. Willatts et al. did not find LC PUFA supplementation during infancy to affect scores on an attention control test. 11 However, the results did indicate an effect of supplementation on the speed of information processing, with shorter response latencies on the Matching Familiar Figures Test among members of the intervention group. Jensen et al. found that children whose mothers received modest DHA supplementation during breastfeeding for the first 4 months after delivery performed better on a test of sustained attention at 5 years of age.[59](#page-35-8)

Problem Solving. In a study supplementing infant with formula containing DHA and AA, Willatts et al. noted that supplementation with LC PUFAs did not improve problem solving ability, but did improve its efficiency.^{[11](#page-33-9)} In addition, Henriksen et al. found that supplementation significantly improved performance on the problem solving subset of the Ages and Stages Questionnaire.^{[56](#page-35-5)}

Childhood and Adolescence

In the 36 studies $60-95$ $60-95$ described in [tables 5](#page-20-0) and [6](#page-25-0) that met the inclusion criteria for this systematic review intervention lengths ranged from 3 weeks to 4.5 years. The main source of $n-3$ LC PUFA was primarily fish or algal oil. Subjects in the reviewed studies divided between healthy developing populations $(n = 13)$ and those with clinical characteristics: history of asthma $(n = 1)$, ADHD $(n = 10)$, potential DHA deficiency (either as a result of preterm birth or low $n-3$ index; $n = 2$), ASD $(n = 1)$, mood disorders $(n = 1)$, or phenylketonuria $(n = 1)$, iron deficiency $(n = 1)$, malnutrition $(n = 1)$; or below average reading level $(n = 2)$ [Figure 1.](#page-15-0)

While significant attention has been given to the importance of LC PUFA level during gestation and the first year of life, less is known about its role in subsequent development. Specifically, the period from 12 months to 24 months remains a significant developmental period, which is also marked by dietary changes that can lead to deficiencies. Devlin et al. investigated the cognitive effect of DHA and ARA

control group

Table 4. (continued)

Table 5.

Supplementation During Childhood and Adolescence: Study Type and Participant Characteristics.

Table 5. (continued)

Table 5. (continued)

Table 5. (continued)

supplementation in toddler. The author reported no effects on cognitive and language composite, but did find red blood cell ARA level to correlate with improved language scores.^{[60](#page-35-9)} Another study conducted with toddlers did not indicate positive outcomes of DHA and AA supplementation, and found some negative effects of supplementation on language development among all but the lowest birth weight and lowest SES groups.^{[61](#page-35-10)}

In a long-term study, Brew et al. attempted to discern whether FO supplementation from 6 months to 5 years of age correlated with children's scores on the NAPLAN.^{[62](#page-35-11)} Similar to studies assessing *in-utero* supplementation's effects on longterm cognitive outcomes, the results did not indicate that supplementation had any effect on

scores. However, LC PUFA level at 8 years of age did correlate with test scores after correcting for birth weight, maternal age and education level. Similarly, in an adolescent population, Åberg et al. found that those who had consumed more than one fish meal per week at the age of 15 (assessed via questionnaire, had significantly higher cognitive performance levels in terms of composite, verbal, and visuospatial intelligence than those who had less, even after accounting for education $level.⁶³$ $level.⁶³$ $level.⁶³$

In one study investigating the effects of omega-3 supplementation on children's learning and behavior, the authors reported equivocal results with a significant increase in DHA and EPA levels in both the placebo as well as the treatment group. Authors suggested that this may have been due to dietary changes based on increased awareness via information provided to

participants' parents on the purpose of the study.^{[64](#page-35-13)}

Two important childhood and adolescence intervention studies— FINS-KIDS and FINS-TEENS addressed the effect of dietarily supplied $n-3$ LC PUFAs from herring or mackerel meals three times per week, as opposed to meat meals three times per week. In the FINS-KIDS study, the meals included a mean concentration of .21 mg/g EPA + DHA in the meat group and 15.2 in the fish group, and caregivers filled out a food frequency questionnaire to provide information on non-intervention $n-3$ consumption.^{[65](#page-35-14)} After adjusting for dietary compliance, Øyen et al. found that the fish group demonstrated more WPPSI-III raw score improvement, as well as three subtests and the non-dominant hand 9-HPT test, but the overall results did not indicate improved general

Table 6.

Supplementation During Childhood and Adolescence: Instrumentation and Results.

Table 6. (continued)

Table 6. (continued)

Table 6. (continued)

cognitive performance after intervention. Sheppard and Cheatham also addressed foodderived $n-3s$ (specifically in relation \vert

to $n-6$: $n-3$ ratios) in terms of effect on cognitive function through an observational study using diet recalls and histories rather than

a supplement intervention, and found that participants with balanced ratio scores scored higher on overall measures of executive

function. 66 66 66 Importantly, the results indicate that when intake for both $n-$ 3 and $n-6$ was high (low ratio) cognitive abilities declined. In comparison to other studies, these results are important due to the focus on balance rather than high levels of supplementation, and may interact with/help explain the threshold findings offered in other studies.

Particularly among adolescents, compliance issues may introduce biases in studies that address these populations. Handeland et al. also found that, while dietary intake is preferable to supplementation, taste preferences may be a factor.^{[67](#page-35-16)} The results of the study by van der Wurff et al. did not indicate an effect of 1 year of krill oil supplementation on participants, or between $n-3$ index and neurocognitive test scores.^{[68](#page-35-17)} However, the authors noted a high level of non-compliance, and suggested that adherence difficulties may have contributed to the lack of a demonstrated correlation between krill oil supplementation and neurocognitive benefits.

Specific Outcomes of Interest. Given the prefrontal cortex development that occurs in childhood and adolescence, and the increasing ability to test for higher-order cognitive functions among older children, studies conducted during the later childhood and adolescence period in particular assessed for higher-order cognitive function, including: attention and executive functioning, information processing speeds and impulsivity, and memory.

Attention and Executive Functioning. Several studies found that DHA supplementation can have positive effects on attention and executive functioning during the childhood and adolescence periods, in both clinical and cognitive healthy populations. For instance, Vesco et al. studied a group of 7-14-year-olds with disorders that affect executive

functioning, and found that $n-3$ supplementation may aid in executive functioning treatment for mood disorders. 69 69 69 In particular, executive functioning in the areas of inhibition control, adaptability to emotions, and cognitive flexibility improved more than in the areas of task initiation, planning, and organization. In the FINS-TEENS study, Handeland et al. found that total performance and processing speed improved in the fish meal group compared to meat and supplement groups; the authors noted that dietary intake appears preferable to supplementation.^{[67](#page-35-16)}

Information Processing Speeds and Impulsivity. Van der Wurff et al. found that, on a letter digit substitution test, a higher omega-3 index was associated with better information processing speeds: each 1% higher the omega-3 index, the LDST score improved by 1.23 digits. $\frac{70}{2}$ On the D2 test of attention, participants with higher omega-3 levels had fewer errors of omission, which indicates less impulsivity. While the overall results did not indicate an impact of fatty fish intake on general cognitive function, Øyen et al. did report a small beneficial effect on three subtests: processing speed subscale, coding and symbol search, and non-dominant hand 9- HPT, with 78% power to detect an effect size of .37.^{[65](#page-35-14)} Due to DHA's role in neural communication, the dietary increases to $n-3$ intake in this study may indicate an interaction with processing speed, though the results are inconclusive and further studies using processing speed measures are indicated. Other studies have also reported an interaction between LC PUFAs and measures of impulsivity, primarily among the adolescent population. One study with a younger population (8-10 years of age) included the Matching Familiar Figures Test (MFFT) to measure visual attention and impulsivity, and found that the number of first correct responses increased with supplementation, although the study overall did not yield positive results.^{[64](#page-35-13)}

Memory. Ryan and Nelson found that, while their results did not indicate significant treatment effects on the primary outcome measures, regression analysis did indicate a significant positive correlation between DHA level and higher PPVT scores (which tests for listening comprehension in English, and is associated with memory and cognitive function).^{[71](#page-35-20)} Sheppard and Cheatham similarly found a balanced $n-3$: n : 6 ratio correlated with better working memory scores.^{[66](#page-35-15)} Widenhorn-Müller et al. found DHA/EPA supplementation to improve working memory among a population with ADHD. 72 72 72

Cognitively Clinical Populations **Studies**

During the childhood and adolescence supplementation period, an increasing number of studies have addressed clinical rather than typically developing populations, assessing for the effect of LC PUFAs on pathologies including ADHD and ASD.

ADHD. Given the high concentration of DHA in the frontal areas of the brain associated with executive function, the correlation between $n-3s$ and ADHD symptomatology have been of interest to various researchers. Crippa et al. tested the effect of DHA as an ADHD monotherapy.^{[73](#page-35-22)} The results showed no difference between treatment and intervention group on the primary outcome measure: ADHD rating scale IV. However, DHA supplementation did appear to produce small benefits to focused attention, parent-rated improvements to psychosocial functioning, and parent-identified reductions in emotional problems.

Raz et al. did not find supplementation with EFA to produce any amelioration of ADHD symptoms beyond that of the placebo effect.^{[74](#page-35-23)}

Kean et al. reported improved Conners' Parent Rating Scale, behavior at home, and learning abilities scores as a result of supplementation with green-lipped mussel extract.^{[75](#page-35-24)} Further, participants in the intervention groups demonstrated improved memory in cognitive tasks, indicating the potential benefit of $n-3$ supplementation on delayed working memory in particular. Similarly, Milte et al. supplemented children with EPA, DHA, or linoleic acid for 4 months, and although outcome measures showed no significant differences between the three treatments, the Authors found that increased erythrocyte levels of EPA, DHA, and $n-3$ FAs overall (resulting in lower $n-6$ to $n-3$ ratios) correlated with improved overall literacy, attention, and parent-rated behavior measures^{[76,](#page-35-25)[77](#page-35-26)}

ASD. Due to insufficiencies of pharmacological treatments, there has been increasing interest in complementary and supplementbased treatments for ASD, including $n-3$ LC PUFAs, DHA and EPA.^{[78](#page-35-27)} 1 study evaluating the efficacy of vitamin D, LC PUFA, or both, on core symptoms of ASD reported that improved social awareness and social communicative functioning was significantly correlated with both $n-3$ and $n-3$ + Vitamin D interventions. Authors suggested that either alone or in combination with Vitamin D, $n-3s$ can have a positive effect on the core symptoms of ASD.^{[79](#page-36-1)}

Discussion

This review evaluated the effect of omega-3 fatty acid supplementation

on neurodevelopment in 3 different cognitive developmental phases: inutero; lactation/infancy; and childhood and adolescence. Overall, the clinical studies reviewed reported equivocal results regarding cognitive function among the 3 populations.

Generally, researchers have reported beneficial effects on several specific cognitive domains, and at times with small effect sizes. The most consistent positive results include those pertaining to language/communication, executive functioning, attention, and memory.

Further, most research is conducted among populations that do not exhibit deficiencies in $n-3$ LC PUFA status, and numerous studies indicate the presence of a threshold or even a U-shaped curve in relation to $n-3$ consumption. It could appear that in populations that are not deficient in DHA or other $n-3$ LC PUFAs, supplementation has a negligible or at times detrimental effect. Few studies have addressed populations that are deficient in $n-$ 3s; 1 study conducted on a population of children with mild to moderate malnourishment resulted in improvements in an extensive number of domains on a neuropsychological test battery.^{[80](#page-36-2)}

Although LC PUFAs supplied during infancy and in-utero seldom have shown significant cognitive effects, it appears that they do not persist at long-term follow-up assessments. This may indicate that other confounding variables such as nutritional and lifestyle factors can influence the outcomes in the intervening years. In dietary-based studies in particular, authors noted that higher levels of fish intake tend to correlate with higher parental education and socioeconomic status levels, which may confer their own benefits. However, while most studies have alluded to the superiority of dietarily-derived

omega-3 sources, a recent study found no effect of supplementation with fatty fish or rapeseed oil from 5-10 months post-delivery on infants' latencies of FVEP, Bayley's MDI, or in PDI index.^{[48](#page-34-8)}

Several studies across intervention periods yielded gender-dependent results, but further research on differences in how n-3 LC PUFAs are metabolized and synthesized according to sex is required to draw clear conclusions.

Overall, the authors of the majority of the studies with short interventions noted that it is important for $n-3s$ to be supplied throughout life, rather than only during the earliest developmental stages.

The main strength of this systematic review is the fairly large number of papers analyzed and searched through multiple databases. Including reference lists in the search assured a comprehensive overview of the published studies. Also, To avoid bias, manuscripts were reviewed by two reviewers.

This review has also several limitations. Inconsistencies in LC PUFA source and type persist across the included studies, and contribute to the equivocality of the overall results. Studies have tested DHA in isolation, or in combination with EPA, ARA, and AA, derived from different sources and administered in a broad range of dosages. Further, some researchers have addressed an advantage of dietarily derived over supplement based n-3s, which may be due to bioavailability. For instance, LC PUFAs in fatty fish are bound to both phospholipids and triacylglycerol, whereas those in supplements are only bound to triacylglycerol.^{[67](#page-35-16)} Another source of bias could be that nearly all studies, even those funded by purely academic or governmental sources, reported that the intervention capsules/supplements were

provided by a supplement or vitamin industry stakeholder.

Conclusion

Studies addressing $n-3$ LC PUFA supplementation at three key neurodevelopmental periods—inutero, during the first year of life, and throughout childhood and adolescence—have reported some benefits in the areas of visual attention, working memory, executive function, and communication. However, effects are more often reported for specific cognitive domains rather than cognitive composite scores and do not tend to persist to long-term follow-up assessment. This may be due in part to the presence of confounding variables like other demographic and lifestyle characteristics and methodological difficulties (like lack of compliance, loss to follow-up, and a very broad range of outcome measures, dosages, and intervention types). Findings remain equivocal, and further research that is powered to detect small, subgroup effect sizes remains necessary.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Ayesha Sherzai1 **b** [https://orcid.org/0000-0003-](https://orcid.org/0000-0003-0600-294X) [0600-294X](https://orcid.org/0000-0003-0600-294X) AJLM

References

1. Clandinin MT. Brain development and assessing the supply of

polyunsaturated fatty acid. Lipids. 1999;34:131-137.

- 2. Almaas AN, Tamnes CK, Nakstad B, et al. Diffusion tensor imaging and behavior in premature infants at 8 years of age, a randomized controlled trial with long-chain polyunsaturated fatty acids. Early Hum Dev. 2016;95: 41-46.
- 3. Cheatham CL, Nerhammer AS, Asserhøj M, Michaelsen KF, Lauritzen L. Fish oil supplementation during lactation: Effects on cognition and behavior at 7 years of age. Lipids. 2011; 46:637-645.
- 4. Li D, Wahlqvist ML, Sinclair AJ. Advances in n-3 polyunsaturated fatty acid nutrition. Asia Pac J Clin Nutr. 2019;28:1-5.
- 5. Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PRC. Increased erythrocyte eicosapentaenoic acid and docosahexaenoic acid are associated with improved attention and behavior in children with ADHD in a randomized controlled three-way crossover trial. J Atten Disord. 2015;19: 954-964.
- 6. Simopoulos A. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016;8:128.
- 7. Martinez M. Tissue levels of polyunsaturated11 fatty acids during early human development. *J Pediatr*. 1992;120:S129-S138.
- 8. Cao A, Yu L, Wang Y, Wang G, Lei G. Composition of long chain polyunsaturated fatty acids (LC-PUFAs) in different encephalic regions and its association with behavior in spontaneous hypertensive rat (SHR). Brain Res. 2013;1528:49-57.
- 9. Gould JF, Anderson AJ, Yelland LN, Gibson RA, Makrides M. Maternal characteristics influence response to DHA during pregnancy. Prostagl Leukot Essent Fat Acids. 2016;108:5-12.
- 10. Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000; 42:174-181.
- 11. Willatts P, Forsyth S, Agostoni C, Casaer P, Riva E, Boehm G. Effects of longchain PUFA supplementation in infant formula on cognitive function in later childhood. Am J Clin Nutr. 2013;98: 536S-542S.
- 12. Hornstra G Essential fatty acids in mothers and their neonates. Am J Clin Nutr. 2000;71:1262S-1269S.
- 13. Makrides M, Gibson RA, McPhee AJ, et al. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA. 2010;304: 1675-1683.
- 14. Ramakrishnan U, Gonzalez-Casanova I, Schnaas L, et al. Prenatal supplementation with DHA improves attention at 5 y of age: A randomized controlled trial. Am J Clin Nutr. 2016; 104:1075-1082.
- 15. Rees A, Sirois S, Wearden A. Prenatal maternal docosahexaenoic acid intake and infant information processing at 4.5mo and 9mo: a longitudinal study. PLoS One. 2019;14:e0210984.
- 16. Campoy C, Escolano-Margarit MV, Ramos R, et al. Effects of prenatal fishoil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age. Am J Clin Nutr. 2011;94:1880S-1888S.
- 17. Dunstan JA, Simmer K, Dixon G, Prescott SL. Cognitive assessment of children at age 2½ years after maternal fish oil supplementation in pregnancy: A randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008;93:F45.
- 18. Helland IB, Saugstad OD, Smith L, et al. Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. Pediatrics. 2001;108:e82-e82.
- 19. Helland IB, Smith L, Blomen B, Saarem K, Saugstad OD, Drevon CA. Effect of supplementing pregnant and lactating mothers with n-3 very-long-chain fatty acids on children's IQ and body mass index at 7 Years of age. Pediatrics. 2008;122:e472-e479.
- 20. van Goor SA, Janneke Dijck-Brouwer DA, Doornbos B, et al. Supplementation of DHA but not DHA with arachidonic acid during pregnancy and lactation influences general movement quality in 12-weekold term infants. Br J Nutr. 2010;103: 235-242.
- 21. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. Pediatrics. 2003;111: e39-e44.
- 22. Boucher O, Burden MJ, Muckle G, et al. Neurophysiologic and

neurobehavioral evidence of beneficial effects of prenatal omega-3 fatty acid intake on memory function at school age. Am J Clin Nutr. 2011;93: 1025-1037.

- 23. Brei C, Stecher L, Brunner S, et al. Impact of the n-6:n-3 long-chain PUFA ratio during pregnancy and lactation on offspring neurodevelopment: 5 year follow-up of a randomized controlled trial. Eur J Clin Nutr. 2017; 71:1114-1120.
- 24. Daniels JL, Longnecker MP, Rowland AS, Golding JALSPAC Study Team. University of Bristol Institute of Child Health. Fish intake during pregnancy and early cognitive development of offspring. Epidemiology. 2004;15: 394-402.
- 25. Dijck-Brouwer DAJ, Hadders-Algra M, Bouwstra H, et al. Lower fetal status of docosahexaenoic acid, arachidonic acid and essential fatty acids is associated with less favorable neonatal neurological condition. Prostagl Leukot Essent Fat Acids. 2005;72:21-28.
- 26. Escolano-Margarit MV, Ramos R, Beyer J, et al. Prenatal DHA status and neurological outcome in children at age 5.5 years are positively associated. J Nutr. 2011;141:1216-1223.
- 27. Gould JF, Makrides M, Colombo J, Smithers LG. Randomized controlled trial of maternal omega-3 long-chain PUFA supplementation during pregnancy and early childhood development of attention, working memory, and inhibitory control. Am J Clin Nutr. 2014;99:851-859.
- 28. Hibbeln JR, Davis JM, Steer C, et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. The Lancet (British edition). 2007;369: 578-585.
- 29. Mendez MA, Torrent M, Julvez J, Ribas-Fitó N, Kogevinas M, Sunyer J. Maternal fish and other seafood intakes during pregnancy and child neurodevelopment at age 4 years. Publ Health Nutr. 2009;12:1702-1710.
- 30. Oken E, Wright RO, Kleinman KP, et al. Maternal fish consumption, hair mercury, and infant cognition in a U.S. cohort. Environmental Health Perspectives. 2005;113:1376-1380.
- 31. Steer CD, Lattka E, Koletzko B, Golding J, Hibbeln JR. Maternal fatty acids in pregnancy, FADS polymorphisms, and child intelligence quotient at 8 y of age. Am J Clin Nutr. 2013;98:1575-1582.
- 32. Vollet K, Ghassabian A, Sundaram R, Chahal N, Yeung EH. Prenatal fish oil supplementation and early childhood development in the Upstate KIDS Study. *J Dev Ori Health Dis.* 2017;8: 465-473.
- 33. Ostadrahimi A, Ostadrahimi A, Salehi-Pourmehr H, et al. The effect of perinatal fish oil supplementation on neurodevelopment and growth of infants: A randomized controlled trial. Eur J Nutr. 2018;57:2387-2397.
- 34. Mulder KA, Elango R, Innis SM. Fetal DHA inadequacy and the impact on child neurodevelopment: A follow-up of a randomised trial of maternal DHA supplementation in pregnancy. BrJ Nutr. 2018;119:271-279.
- 35. Colombo J, Shaddy DJ, Gustafson K, et al. The Kansas University DHA Outcomes Study (KUDOS) clinical trial: Long-term behavioral follow-up of the effects of prenatal DHA supplementation. Am J Clin Nutr. 2019; 109:1380-1392.
- 36. Colombo J, Gustafson KM, Gajewski BJ, et al. Prenatal DHA supplementation and infant attention. Pediatr Res. 2016;80:656-662.
- 37. Hurtado JA, Iznaola C, Peña M, et al. Effects of maternal Ω -3 supplementation on fatty acids and on visual and cognitive development. J Pediatr Gastroenterol Nutr. 2015;61: 472-480.
- 38. Auestad N, Scott DT, Janowsky JS, et al. Visual, cognitive, and language assessments at 39 months: A follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics. 2003;112:e177-e183.
- 39. Birch EE, Garfield S, Castañeda Y, Hughbanks-Wheaton D, Uauy R, Hoffman D. Visual acuity and cognitive outcomes at 4 years of age in a doubleblind, randomized trial of long-chain polyunsaturated fatty acidsupplemented infant formula. Early Hum Dev. 2007;2006;83:279-284.
- 40. Collins CT, Gibson RA, Anderson PJ, et al. Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: A follow-up of a randomised controlled trial. BMJ Open. 2015;5:e007314-e007314.
- 41. de Jong C, Kikkert HK, Fidler V, Hadders-Algra M. The Groningen LCPUFA study: No effect of postnatal long-chain polyunsaturated fatty acids

in healthy term infants on neurological condition at 9 years. Br J Nutr. 2010; 104:566-572.

- 42. de Jong C, Kikkert HK, Seggers J, Boehm G, Decsi T, Hadders-Algra M. Neonatal fatty acid status and neurodevelopmental outcome at 9 years. Early Hum Dev. 2015;91: 587-591.
- 43. Drover J, Hoffman DR, Castañeda YS, Morale SE, Birch EE. Three randomized controlled trials of early long-chain polyunsaturated fatty acid supplementation on means-end problem solving in 9-month-olds. Child Dev. 2009;80:1376-1384.
- 44. Fewtrell MS, Abbott RA, Kennedy K, et al. Randomized, double-blind trial of long-chain polyunsaturated fatty acid supplementation with fish oil and borage oil in preterm infants. *J Pediatr*. 2004;144:471-479.
- 45. Gale CR, Marriott LD, Martyn CN, et al. Breastfeeding, the use of docosahexaenoic acid-fortified formulas in infancy and neuropsychological function in childhood. Arch Dis Child. 2010;95: 174-179.
- 46. Jacobson JL, Jacobson SW, Muckle G, Kaplan-Estrin M, Ayotte P, Dewailly E. Beneficial effects of a polyunsaturated fatty acid on infant development: evidence from the Inuit of Arctic Quebec. J Pediatri. 2008;152: 356-364.e1.
- 47. Jensen CL, Voigt RG, Prager TC, et al. Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed term infants. Am j clinic nutri. 2005;82:125.
- 48. Kalhoff H, Mesch CM, Stimming M, et al. Effects of LC-PUFA supply via complementary food on infant development-a food based intervention (RCT) embedded in a total diet concept. Eur J Clin Nutr. 2020;74: 682-690.
- 49. Lauritzen L, Jørgensen MH, Olsen SF, Straarup EM, Michaelsen KF. Maternal fish oil supplementation in lactation: Effect on developmental outcome in breast-fed infants. Reproduction, Nutrition, development. 2005;45: 535-547.
- 50. Lepping RJ, Honea RA, Martin LE, et al. Long-chain polyunsaturated fatty acid supplementation in the first year of life affects brain function, structure, and metabolism at age nine years. Dev Psychobiol. 2019;61:5-16.
- 51. van der Merwe, Liandré F, Moore SE, Fulford AJ, et al. Long-chain PUFA supplementation in rural African infants: A randomized controlled trial of effects on gut integrity, growth, and cognitive development. Am J Clin Nutr. 2013;97:45-57.
- 52. Meldrum SJ, D'Vaz N, Simmer K, Dunstan JA, Hird K, Prescott SL. Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: A randomised controlled trial. Br J Nutr. 2012;108:1-12.
- 53. Dalmeijer GW, Wijga AH, Gehring U, et al. Fatty acid composition in breastfeeding and school performance in children aged 12 years. Eur J Nutr. 2016;55:2199-2207.
- 54. Henriksen C, Almaas AN, Westerberg AC, Drevon CA, Iversen PO, Nakstad B. Growth, metabolic markers, and cognition in 8-year old children born prematurely, follow-up of a randomized controlled trial with essential fatty acids. Eur J Pediatr. 2016;175:1165-1174.
- 55. Isaacs EB, Ross S, Kennedy K, Weaver LT, Lucas A, Fewtrell MS. 10-year cognition in preterms after random assignment to fatty acid supplementation in infancy. Pediatri. 2011;128:e890-e898.
- 56. Henriksen C, Haugholt K, Lindgren M, et al. Improved cognitive development among preterm infants attributable to early supplementation of human milk with docosahexaenoic acid and arachidonic acid. Pediatrics. 2008;121: 1137-1145.
- 57. Liao K, McCandliss BD, Carlson SE, et al. Event-related potential differences in children supplemented with long-chain polyunsaturated fatty acids during infancy. Dev Sci. 2017;20: e12455.
- 58. Westerberg AC, Schei R, Henriksen C, et al. Attention among very low birth weight infants following early supplementation with docosahexaenoic and arachidonic acid. Acta Paediatr. 2011;100:47-52.
- 59. Jensen CL, Voigt RG, Llorente AM, et al. Effects of early maternal docosahexaenoic acid intake on neuropsychological status and visual acuity at five years of age of breast-fed term infants. *J Pediatr*. 2010;157: 900-905.
- 60. Devlin AM, Chau CMY, Dyer R, et al. Developmental outcomes at 24 Months of age in toddlers supplemented with

arachidonic acid and docosahexaenoic acid: Results of a double blind randomized, controlled trial. Nutrients. 2017;9:975.

- 61. Keim SA, Boone KM, Klebanoff MA, et al. Effect of docosahexaenoic acid supplementation vs placebo on developmental outcomes of toddlers born preterm: A randomized clinical trial. JAMA Pediatr. 2018;172: 1126-1134.
- 62. Brew BK, Toelle BG, Webb KL, et al. Omega-3 supplementation during the first 5 years of life and later academic performance: A randomised controlled trial. Eur J Clin Nutr. 2015;69:419-424.
- 63. Åberg MA, Åberg N, Brisman J, et al. Fish intake of Swedish male adolescents is a predictor of cognitive performance. Acta Pædiatrica. 2009; 98:555-560.
- 64. Kirby A, Woodward A, Jackson S, Wang Y, Crawford MA. A double-blind, placebo-controlled study investigating the effects of omega-3 supplementation in children aged 8–10 years from a mainstream school population. Res Dev Disabil. 2010;31: 718-730.
- 65. Øyen J, Kvestad I, Midtbø LK, et al. Fatty fish intake and cognitive function: FINS-KIDS, a randomized controlled trial in preschool children. BMC Med. 2018;16:41.
- 66. Sheppard KW, Cheatham CL. Omega-6 to omega-3 fatty acid ratio and higherorder cognitive functions in 7- to 9-yolds: A cross-sectional study. Am J clinic nutrition. 2013;98:659-667.
- 67. Handeland K, Øyen J, Skotheim S, et al. Fatty fish intake and attention performance in 14-15 year old adolescents: FINS-TEENS a randomized controlled trial. Nutr J. 2017;16:64.
- 68. van der Wurff, Inge SM, Von Schacky C, Bergeland T, et al. Effect of 1 year krill oil supplementation on cognitive achievement of Dutch adolescents: A double-blind randomized controlled trial. Nutrients. 2019;11:1230.
- 69. Vesco AT, Young AS, Arnold LE, Fristad MA. Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: Secondary analyses of the omega 3 and therapy (OATS) trials. JCPP (J Child Psychol Psychiatry). 2018;59:628-636.
- 70. van der Wurff I, von Schacky C, Berge K, Zeegers M, Kirschner P, de Groot R. Association between blood omega-3

index and cognition in typically developing Dutch adolescents. Nutrients. 2016;8:13.

- 71. Ryan AS, Nelson EB. Assessing the effect of docosahexaenoic acid on cognitive functions in healthy, preschool children: A randomized, placebo-controlled, double-blind study. Clin Pediatr. 2008;47:355-362.
- 72. Widenhorn-Müller K, Schwanda S, Scholz E, Spitzer M, Bode H. Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): A randomized placebo-controlled intervention trial. Prostagl Leukot Essent Fat Acids. 2014;91:49-60.
- 73. Crippa A, Crippa A, Tesei A, et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/ hyperactivity disorder: A randomized, placebo-controlled clinical trial. Eur Child Adolesc Psychiatr. 2019;28:571-583.
- 74. Raz R, Carasso RL, Yehuda S. The influence of short-chain essential fatty acids on children with attentiondeficit/hyperactivity disorder: A double-blind placebo-controlled study. J Child Adolesc Psychopharmacol. 2009;19:167-177.
- 75. Kean JD, Kean JD, Sarris J, et al. Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attentiondeficit hyperactivity disorder (ADHD): A randomised, double-blind, placebocontrolled trial. Psychopharmacology. 2017;234:403-420.
- 76. Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PRC. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attentiondeficit/hyperactivity disorder: A randomized controlled trial. Nutrition. 2012;28:670-677.
- 77. Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PRC. Increased erythrocyte eicosapentaenoic acid and docosahexaenoic acid are associated with improved attention and behavior in children with ADHD in a randomized controlled three-way crossover trial. J Atten Disord. 2015;19: 954-964.
- 78. Demmelmair H, MacDonald A, Kotzaeridou U, et al. Determinants of

plasma docosahexaenoic acid levels and their relationship to neurological and cognitive functions in PKU patients: A double blind randomized supplementation study. Nutrients. 2018;10:1944.

- 79. Mazahery H, Conlon CA, Beck KL, et al. A randomised-controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of core symptoms of autism spectrum disorder in children. *J Autism* Dev Disord. 2019;49:1778-1794.
- 80. Portillo-Reyes V, Pérez-García M, Loya-Méndez Y, Puente AE. Clinical significance of neuropsychological improvement after supplementation with omega-3 in 8–12 years old malnourished Mexican children: A randomized, double-blind, placebo and treatment clinical trial. Res Dev Disabil. 2014;35:861-870.
- 81. Baumgartner J, Smuts CM, Malan L, et al. Effects of iron and n-3 fatty acid supplementation, alone and in combination, on cognition in school children: a randomized, double-blind, placebo-controlled intervention in South Africa. Am J Clin Nutr. 2012;96: 1327-1338.
- 82. Sørensen LB, Damsgaard CT, Dalskov S, et al. Diet-induced changes in iron and n-3 fatty acid status and associations with cognitive performance in 8–11-year-old Danish children: secondary analyses of the optimal well-being, development and health for Danish children through a healthy new nordic diet school meal study. Br J Nutr. 2015;114:1623-1637.
- 83. Bos DJ, Oranje B, Veerhoek ES, et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and

without attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2015;40:2298-2306.

- 84. Cornu C, Mercier C, Ginhoux T, et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. Eur Child Adolesc Psychiatr. 2018;27:377-384.
- 85. Dalton A, Wolmarans P, Witthuhn RC, van Stuijvenberg ME, Swanevelder SA, Smuts CM. A randomised control trial in schoolchildren showed improvement in cognitive function after consuming a bread spread, containing fish flour from a marine source. Prostagl Leukot Essent Fat Acids. 2009;80:143-149.
- 86. Darcey VL, McQuaid GA, Fishbein DH, VanMeter JW. Dietary long-chain omega-3 fatty acids are related to impulse control and anterior cingulate function in adolescents. Front Neurosci. 2018;2019;12:1012.
- 87. de Groot RHM, Ouwehand C, Jolles J. Eating the right amount of fish: inverted U-shape association between fish consumption and cognitive performance and academic achievement in Dutch adolescents. Prostagl Leukot Essent Fat Acids. 2012;86:113-117.
- 88. Kim J, Winkvist A, Aberg MA, et al. Fish consumption and school grades in Swedish adolescents: A study of the large general population. Acta Pædiatrica 2010;2009;99:72-77.
- 89. Kennedy DO, Jackson PA, Elliott JM, et al. Cognitive and mood effects of 8 weeks' supplementation with 400 mg or 1000 mg of the omega-3 essential fatty acid docosahexaenoic acid (DHA) in healthy children aged 10-12 years. Nutr Neurosci. 2009;12:48-56.
- 90. Montgomery P, Burton JR, Sewell RP, Spreckelsen TF, Richardson AJ. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: A cross-sectional analysis from the DOLAB study. PLoS One. 2013;8: e66697.
- 91. Parletta N, Cooper P, Gent DN, Petkov J, O'Dea K. Effects of fish oil supplementation on learning and behaviour of children from Australian Indigenous remote community schools: A randomised controlled trial. Prostagl Leukot Essent Fat Acids. 2013; 89:71-79.
- 92. Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics. 2005;115:1360-1366.
- 93. Richardson AJ, Burton JR, Sewell RP, Spreckelsen TF, Montgomery P. Docosahexaenoic acid for reading, cognition and behavior in children aged 7–9 years: A randomized, controlled trial (the DOLAB study). PLoS One. 2012;7:e43909.
- 94. Sinn N, Bryan J, Wilson C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: A randomised controlled trial. Prostagl Leukot Essent Fat Acids. 2008;78:311-326.
- 95. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebocontrolled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr. 2001;139: 189-196.